[Federal Register Volume 64, Number 203 (Thursday, October 21, 1999)]
[Notices]
[Pages 56795-56796]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-27468]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control And Prevention
[60Day-00-02]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of section 3506(c)(2)(A) of the
Paperwork reduction Act of 1995, the Center for Disease Control and
Prevention is providing opportunity for public comment on proposed data
collection projects. To request more information on the proposed
projects or to obtain a copy of the data collection plans and
instruments, call the CDC Reports Clearance Officer on (404) 639-7090.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques for other
forms of information technology. Send comments to Seleda Perryman, CDC
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24,
Atlanta, GA 30333. Written comments should be received within 60 days
of this notice.
Proposed Projects
1. Surveillance and Evaluation of Blood Donors Positive for Human
Immunodeficiency Virus (HIV) Antibody or HIV Antigen Surveillance and
Evaluation of Blood Donors Positive for Human Immunodeficiency Virus
(HIV) Antibody or HIV Antigen (0920-0329)--Extension--National Center
for HIV, STD, and TB Prevention (NCHSTP). In 1987, the President
directed the Department of Health and Human Services (DHHS) to
determine the nationwide incidence of, to predict the future of, and to
determine the extent to which human immunodeficiency virus (HIV) is
present in various segments of our population. In response, CDC formed
an epidemiological team to summarize existing information. An extensive
review of published and unpublished data led to the conclusion that
even though there is information suggesting a very large number of
Americans were infected, there was no substitute for carefully and
scientifically obtained incidence and prevalence data. The need to
monitor HIV seroprevalence existed on the national and at the state and
local levels for public health management: Targeting and evaluating
prevention programs, planning future health care needs and determining
health policy.
On a national basis, HIV seroprevalence projects in 1987 consisted
of monitoring the HIV status of: Civilian applicants for military
service; blood donors, including follow-up risk factor evaluation in
seropositives; and Job Corps entrants. HIV prevalence was studied in
settings of special public health interest including selected colleges
and prisons, among health care workers in hospital emergency rooms and
among Native Americans and homeless persons. Other national data
sources were examined, such as cohort studies of groups at risk,
including homosexual and bisexual men and IV drug users, providing
information on knowledge of AIDS and
[[Page 56796]]
risk behaviors, changes in behavior, and incidence of HIV infection.
In 1987, OMB approved the ``Family of HIV Seroprevalence Surveys''
(0920-0232). These surveys included seven seroprevalence surveys that
involved interaction with individuals (non-blinded surveys). One of
these surveys was the surveillance and evaluation of blood donors.
The objectives of this study are to: (1) Estimate the prevalence
and incidence of HIV infection among blood donors at participating
blood centers; (2) evaluate the characteristics of infected donors to
strengthen the effectiveness of the donor screening and deferral
processes; (3) analyze the risk behavior characteristics of infected
donors to assess distribution and trends of HIV; (4) monitor additional
human immunodeficiency viruses, HIV genetic variation, and other
infections relevant to the epidemiology of HIV among U.S. blood donors
and seroconverted recipients; (5) estimate the risk of HIV transmission
from screened blood; (6) and evaluate new tests to decrease
transmission by window period donors.
In 1993 and 1996, OMB again approved for 3 years each, the
surveillance and evaluation of blood donors who test positive for Human
Immunodeficiency Virus (HIV) Antibody and their needle-sharing and
sexual partners (0920-0329). This request is for an additional 3-year
approval. The CDC anticipates 125 positive donors will enroll annually
in this study (based upon previous 3 year enrollment rates and
epidemiological progress of the disease). The interview takes
approximately 1 hour to complete for those who agree to the interview
and 10 minutes to complete for those who refuse to enroll. The total
cost to the respondent is $8,206.19 over the 3-year period.
----------------------------------------------------------------------------------------------------------------
Number of Avg. burden
Respondents Number of responses/ response (in Total burden
respondents Respondent hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Blood donors (interviewed)...................... 375 1 1.0 375
Blood donors (refuse interview)................. 275 1 0.16 44
---------------------------------------------------------------
Total....................................... .............. .............. .............. 419.00
----------------------------------------------------------------------------------------------------------------
Dated: October 14, 1999.
Nancy Cheal,
Acting Associate Director for Policy, Planning, and Evaluation, Centers
for Disease Control and Prevention (CDC).
[FR Doc. 99-27468 Filed 10-20-99; 8:45 am]
BILLING CODE 4163-18-P
